Question 1

Has Persia Coleman received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $2,629 in general payments to Persia Coleman across 138 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Persia Coleman did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Persia Coleman come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
AbbVie	33	$562
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	21	$417
Supernus Pharmaceuticals, Inc.	22	$302
Alkermes, Inc.	12	$282
Johnson & Johnson	10	$228
Otsuka America Pharmaceutical, Inc.	8	$162
Takeda Pharmaceuticals U.S.A., Inc.	8	$147
Neurocrine Biosciences, Inc.	3	$78
Lundbeck LLC	3	$73
Almatica Pharma LLC	2	$54
Corium, LLC	2	$49
Indivior Inc.	2	$46
Axsome Therapeutics, Inc.	2	$45
Alfasigma USA, Inc.	2	$43
Sunovion Pharmaceuticals Inc.	3	$38
Merck	2	$30
Bausch Health US, LLC	1	$28
Teva Pharmaceuticals USA, Inc.	1	$25
Novo Nordisk	1	$18

Drug	Claims	Cost to plans & patients
Lorazepam	11	$51
Alprazolam	19	$43

Persia Coleman

Payments from drug & device makers

Who reported the general payments

How this compares

Most prescribed under Part D

Other psychiatric/mental health in Las Vegas